Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zoe Ngo"'
Autor:
Robin K. Kelley, Nancy M. Joseph, Halla S. Nimeiri, Jimmy Hwang, Laura M. Kulik, Zoe Ngo, Spencer C. Behr, Courtney Onodera, Karen Zhang, Andrea G. Bocobo, Al B. Benson, Alan P. Venook, John D. Gordan
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Background: The mammalian target of rapamycin (mTOR) pathway is upregulated in nearly half of hepatocellular carcinoma (HCC) tumors and is associated with poor prognosis. In preclinical models of HCC, the combination of mTOR pathway inhibition with t
Externí odkaz:
https://doaj.org/article/cbb627c3bf394483ab5c3ac74db1bf71
Autor:
Al B. Benson, Alan P. Venook, Andrea Grace Bocobo, Nancy M. Joseph, Laura Kulik, Robin Kate Kelley, Karen Zhang, Zoe Ngo, Jimmy Hwang, Halla Sayed Nimeiri, Spencer C. Behr, John D. Gordan, Courtney Onodera
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Liver Cancer
Liver Cancer
Background: The mammalian target of rapamycin (mTOR) pathway is upregulated in nearly half of hepatocellular carcinoma (HCC) tumors and is associated with poor prognosis. In preclinical models of HCC, the combination of mTOR pathway inhibition with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46de49e8bbe4dc76861bf785dfb5c1
https://www.karger.com/Article/FullText/518297
https://www.karger.com/Article/FullText/518297
Autor:
Jordyn Silverstein, Annalisa L. Post, Katy K. Tsai, Zoe Ngo, A. Jo Chien, Rebecca L. Olin, Katherine Van Loon
Publikováno v:
JCO oncology practice. 16(9)
Cancer during pregnancy is relatively rare but is increasing in frequency in countries in which the maternal child-bearing age continues to rise. The complexities of medical decision making are underscored by the need to weigh the potential benefits
Autor:
Madeline J Griffith, John D. Gordan, Spencer C. Behr, Lawrence Fong, Diana L. Hanna, Alan P. Venook, Bridget P. Keenan, Paige M. Bracci, Syma Iqbal, Kelly Bauer, Anthony B. El-Khoueiry, Robin Kate Kelley, Zoe Ngo, Sarah E. Umetsu
Publikováno v:
Journal of Clinical Oncology. 37:TPS464-TPS464
TPS464 Background: The antiangiogenic tyrosine kinase inhibitor (TKI) SOR prolongs survival in advanced HCC, but responses occur in fewer than 5% of patients (pts) and median progression-free survival (PFS) is less than 6 months. Immune checkpoint in
Autor:
Jimmy Hwang, Spencer C. Behr, Zoe Quandt, Emily Mitchell, Katherine Van Loon, Zoe Ngo, Robin Kate Kelley, Sarah E. Umetsu, Chloe E. Atreya, Bridget P. Keenan, Andrew H. Ko, Thomas Weber, Alan P. Venook, Pelin Cinar, Chienying Liu, Lawrence Fong, John D. Gordan
Publikováno v:
Journal of Clinical Oncology. 36:4087-4087
4087Background: The efficacy of immune checkpoint inhibition (CPI) has not been established in ABC. The combination of CPI plus the myeloid cytokine GM-CSF was safe with prolonged overall survival ...
Autor:
Lawrence Fong, Spencer C. Behr, Pelin Cinar, Bridget P. Keenan, Jimmy Hwang, Chloe E. Atreya, Thomas Weber, Zoe Ngo, Chienying Liu, Emily Mitchell, Robin Kate Kelley, Alan P. Venook, Katherine Van Loon, Zoe Quandt, John D. Gordan, Andrew H. Ko, Alexander Cheung
Publikováno v:
Journal of Clinical Oncology. 36:386-386
386 Background: The efficacy of immune checkpoint inhibition (CPI) has not been established in ABC. GM-CSF modulates immune effector cells and has demonstrated safety and improved survival (OS) in combination with ipilimumab in melanoma. This phase 2